Search results
Results from the WOW.Com Content Network
Antiplatelet drugs effect may be affected by patient's medications, current medical conditions, food and supplements taken. Antiplatelet drugs effect may be increased or decreased. An increase in antiplatelet effect would increase the risk of bleeding and could cause prolonged or excessive bleeding.
Generally, drugs outlined within the ATC code B01AC should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiplatelet drugs .
Anti-BP180, Anti-BP230 Confirmed 6-30 per 100,000 (mostly older adults) [7] Cicatricial pemphigoid: Mucous membranes, sometimes skin Anti-BP180, Anti-BP230 Confirmed Rare [8] Dermatitis herpetiformis: Skin Anti-tissue transglutaminase: Confirmed 10 per 100,000 [9] Dermatomyositis: Skin and muscles: Anti-Jo1, Anti-Mi2, Anti-SRP, Anti-TIF1 Confirmed
The list below describes some of the more common medications used to prevent blood clots. [24] Note that generally since blood clotting is inhibited, a side effect typically is increased bleeding, though it can be reversed by administering a medication that stops the bleeding or by discontinuation of the medication itself.
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [10] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [10]
Activation of platelets and the subsequent aggregation of platelets has a crucial role maintaining normal haemostasis. Disturbance in this system can lead to cerebrovascular, cardiovascular and peripheral vascular diseases where it can lead to a stroke, unstable angina and myocardial infarction. When a vessel is damaged ADP is released from ...
Anti-platelet effects start within 2 days and reach their maximum by 6 days of therapy. Ticlopidine’s effects persist for 3 days after discontinuing ticlopidine although it may take 1–2 weeks for platelet function to return to normal, as the medication affects platelets irreversibly.
In a phase 1-2 open-label study treatment with CM313, a novel anti-CD38 monoclonal antibody, rapidly boosted platelet levels in adults with ITP by inhibiting antibody-dependent cell-mediated cytotoxicity on platelets; maintained long-term efficacy by clearing plasma cells; and was associated with low-grade toxic effects.